Gene Therapy (Part II)

Author(s): Zhi-Yao He, Xi-Biao Jia

Journal Name: Current Gene Therapy

Volume 20 , Issue 2 , 2020


Become EABM
Become Reviewer
Call for Editor

[1]
Ma CC, Wang ZL, Xu T, He ZY, Wei YQ. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv 2020; 40, 107502
[http://dx.doi.org/10.1016/j.biotechadv.2019.107502] [PMID: 31887345]
[2]
Jia XB, He ZY. Gene Therapy (Part I). Curr Gene Ther 2020; 20(1): 4.
[http://dx.doi.org/10.2174/156652322001200604150311] [PMID: 32603275]
[3]
Zhang CH, Li M, Lin YP, Gao Q. Systemic therapy for hepatocellular carcinoma: advances and hopes. Curr Gene Ther 2020; 20(2): 84-99.
[http://dx.doi.org/10.2174/1566523220666200628014530] [PMID: 32600231]
[4]
Cui XW, Ren JY, Gu YH, Li QF, Wang ZC. NF1, neurofibromin and gene therapy: prospects of next-generation therapy. Curr Gene Ther 2020; 20(2): 100-0108.
[http://dx.doi.org/10.2174/1566523220666200806111451] [PMID: 32767931]
[5]
Ni YH, Zhao X, Wang W. CD24, A review of its role in tumor diagnosis, progression and therapy. Curr Gene Ther 2020; 20(2): 109-26.
[http://dx.doi.org/10.2174/1566523220666200623170738] [PMID: 32576128]
[6]
Xia Y, Li X, Sun W. Applications of recombinant adenovirus-p53 gene therapy for cancers in the clinic in China. Curr Gene Ther 2020; 20(2): 127-41.
[http://dx.doi.org/10.2174/1566523220999200731003206]
[7]
Li H, Wu Y, Huang N, et al. γ-Aminobutyric acid promotes osteogenic differentiation of mesenchymal stem cells by inducing TNFAIP3. Curr Gene Ther 2020; 20(2): 152-61.
[http://dx.doi.org/10.2174/1566523220999200727122502]
[8]
Zhou M, Hu Z, Zhang C, Wu L, Li Z, Liang D. Gene therapy for hemophilia A: where we stand. Curr Gene Ther 2020; 20(2): 142-51.
[http://dx.doi.org/10.2174/1566523220666200806110849] [PMID: 32767930]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 2
Year: 2020
Page: [83 - 83]
Pages: 1
DOI: 10.2174/156652322002200821100006

Article Metrics

PDF: 19
HTML: 2